Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Notches Up Record Earnings in 2017 on Bullish Exports, Milestones
February 2, 2018
- Roche Diagnostics’ ALK CDx Ventana Filed for Add’l Use for Alecensa
February 2, 2018
- Meiji’s Parkinson’s Candidate Hits Goal in Japan PII/III, Filing Planned for 2018
February 2, 2018
- IMS Japan, Quintiles Japan to Change Names in April
February 1, 2018
- Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
- Hisamitsu’s Transdermal Schizophrenia Med Hits Primary Endpoint: US PIII
February 1, 2018
- Ferring Beefing Up Reproductive Health Biz in Japan, Sets Up Specialized Sales Team
January 31, 2018
- Sunovion’s Parkinson’s Candidate Hits PIII Primary Endpoint, US Filing Set for Spring
January 31, 2018
- Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
January 31, 2018
- US FDA Fast-Tracks Takeda’s Zika Vaccine Candidate
January 31, 2018
- Otsuka Bags US$10 Million Grant from Gates Foundation for Development of Anti-TB Drug
January 31, 2018
- Hiroshima Couple Served with Arrest Warrant over Counterfeit Harvoni
January 30, 2018
- Novartis Seeks Ankylosing Spondylitis Nod for Cosentyx in Japan
January 30, 2018
- New GSK Japan President to Take Office on Feb. 1
January 30, 2018
- Sanofi to Launch Antibody Drug Dupilumab for Atopic Dermatitis this Spring, Sets Up Special Marketing Force for Potential Blockbuster
January 30, 2018
- New PMP Scheme Will Cause “Pause” before PIII Go/No-Go Decision: Pfizer Japan Head
January 29, 2018
- Takeda Fails in Key Actos Trial for Alzheimer’s
January 26, 2018
- Contract Sales Reps in Japan Log Largest Dip in 2017: Industry Group
January 25, 2018
- Takeda Ramps Up Inisync Pitch in November: Anterio Ranking
January 25, 2018
- Mitobridge Acquisition Completed: Astellas
January 25, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…